Last updated: 2026-09-16 14:56:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
GridAI Technologies Corp. (GRDX) operates in the ELECTRIC & OTHER SERVICES COMBINED sector and is listed on NASDAQ. The stock is currently priced at $2.95, with a market capitalization of $21.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.87 to $6.93. This page covers its latest market performance, valuation, price trends and company information.
$21.18M | |
$3.00 | |
$6.93 | |
$1.87 | |
$3.02 | |
15.49K | |
99.41K | |
-- | |
$6.93 | |
$1.87 | |
-- | |
-- |
GridAI Technologies Corp. (GRDX) is currently trading at $2.95 as of 2026-09-16 14:53:00, down 2.48% ($0.08) from the previous close of $3.02
During today's regular trading session, GRDX has traded between $1.87 and $6.93, with a trading volume of 15.49K shares. The current price is near the lower end of today's range.
Over the past seven days, GridAI Technologies Corp. (GRDX) moved from $3.25 to $2.95, representing a decline of 9.38% ($0.31).
The stock traded between $2.75 and $3.46 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 91.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 21.2%
GRDX is currently trading at $2.95, placing it 21.2% of the way from its 52-week low of $1.87 to its 52-week high of $6.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
| Industry | ELECTRIC & OTHER SERVICES COMBINED |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GridAI Technologies Corp. (GRDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.